GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (OTCPK:ATNXQ) » Definitions » Beneish M-Score

Athenex (Athenex) Beneish M-Score : 0.00 (As of Apr. 28, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Athenex Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Athenex's Beneish M-Score or its related term are showing as below:

During the past 8 years, the highest Beneish M-Score of Athenex was 0.00. The lowest was 0.00. And the median was 0.00.


Athenex Beneish M-Score Historical Data

The historical data trend for Athenex's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex Beneish M-Score Chart

Athenex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial -2.04 -2.38 -2.31 -2.75 -2.67

Athenex Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.75 -1.75 -3.02 -3.67 -2.67

Competitive Comparison of Athenex's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Athenex's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athenex's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Athenex's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Athenex's Beneish M-Score falls into.



Athenex Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Athenex for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1504+0.528 * 1.3078+0.404 * 0.7651+0.892 * 1.0634+0.115 * 0.9421
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6579+4.679 * -0.123496-0.327 * 0.7886
=-2.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec22) TTM:Last Year (Dec21) TTM:
Total Receivables was $27.9 Mil.
Revenue was 8.633 + 33.53 + 31.516 + 29.724 = $103.4 Mil.
Gross Profit was 6.172 + 5.794 + 8.424 + 6.429 = $26.8 Mil.
Total Current Assets was $124.9 Mil.
Total Assets was $204.1 Mil.
Property, Plant and Equipment(Net PPE) was $6.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.3 Mil.
Selling, General, & Admin. Expense(SGA) was $46.0 Mil.
Total Current Liabilities was $114.9 Mil.
Long-Term Debt & Capital Lease Obligation was $3.1 Mil.
Net Income was -34.181 + -19.669 + -32.157 + -17.42 = $-103.4 Mil.
Non Operating Income was -1.763 + 0 + 2.051 + -3.501 = $-3.2 Mil.
Cash Flow from Operations was -14.394 + -16.274 + -20.457 + -23.889 = $-75.0 Mil.
Total Receivables was $22.8 Mil.
Revenue was 4.094 + 31.425 + 20.698 + 41.025 = $97.2 Mil.
Gross Profit was 0.457 + 6.327 + 1.581 + 24.62 = $33.0 Mil.
Total Current Assets was $133.4 Mil.
Total Assets was $267.4 Mil.
Property, Plant and Equipment(Net PPE) was $8.9 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.1 Mil.
Selling, General, & Admin. Expense(SGA) was $65.8 Mil.
Total Current Liabilities was $96.0 Mil.
Long-Term Debt & Capital Lease Obligation was $100.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(27.865 / 103.403) / (22.778 / 97.242)
=0.26948 / 0.23424
=1.1504

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(32.985 / 97.242) / (26.819 / 103.403)
=0.339205 / 0.259364
=1.3078

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (124.929 + 6.043) / 204.055) / (1 - (133.395 + 8.861) / 267.448)
=0.358153 / 0.468098
=0.7651

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=103.403 / 97.242
=1.0634

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.138 / (3.138 + 8.861)) / (2.322 / (2.322 + 6.043))
=0.261522 / 0.277585
=0.9421

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(46.008 / 103.403) / (65.765 / 97.242)
=0.444939 / 0.676302
=0.6579

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3.144 + 114.879) / 204.055) / ((100.101 + 96.048) / 267.448)
=0.578388 / 0.73341
=0.7886

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-103.427 - -3.213 - -75.014) / 204.055
=-0.123496

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Athenex has a M-score of -2.67 suggests that the company is unlikely to be a manipulator.


Athenex Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Athenex's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Athenex (Athenex) Business Description

Traded in Other Exchanges
N/A
Address
1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.
Executives
Jinn Wu director 107 MORGAN LANE, PLAINSBORO NJ 08536
Lau Johnson Yiu Nam director, officer: CEO and Chairman of the Board
Joe Annoni officer: Chief Financial Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Timothy Devere Cook officer: See Remarks C/O ATHENEX, INC., 1001 MAIN STREET,, SUITE 600, BUFFALO NY 14203
Daniel Lang officer: Pres Cell Therapy, VP Corp Dev C/O ATHENEX, INC. CONVENTUS BUILDING, 1001 MAIN ST. STE. 600, BUFFALO NY 14203
Jordan Kanfer director C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Rudolf Kwan director, officer: EVP, Chief Medical Officer C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Michael Smolinski officer: Chief Scientific Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Steven J. Adams officer: Interim Chief Acct Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Kim Campbell director 3300 HYLAND AVE, COSTA MESA CA 92626
William Wei Zuo officer: President, China 3040 POST OAK BLVD, SUITE 1110, HOUSTON TX 77056
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Manson Fok director C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Randoll Sze officer: Chief Financial Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Stephanie A Davis director C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203

Athenex (Athenex) Headlines

From GuruFocus

Athenex Announces a Reverse Stock Split

By sperokesalga sperokesalga 02-14-2023

Athenex Announces Receipt of Positive Nasdaq Listing Determination

By Value_Insider Value_Insider 11-03-2022

Athenex Announces Closing of the Sale of its China API Business

By Value_Insider Value_Insider 11-21-2022

Athenex Exits 503B Sterile Compounding Business

By Value_Insider Value_Insider 12-16-2022